AbbVie Says 20% Of U.S. Managed Care Lives Covered Exclusively By Viekira Pak
This article was originally published in The Pink Sheet Daily
Formulary decisions for HCV agents are occurring rapidly since Viekira’s approval, with AbbVie saying it currently has access to about 40% of U.S. managed care lives. Gilead and AbbVie likely will take patients from each other’s exclusive formulary positions, however, due to labeling differences for Harvoni and Viekira.
You may also be interested in...
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.